Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tenaya Therapeutics (TNYA – Research Report). The associated price target remains the same with $3.00.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors surrounding Tenaya Therapeutics’ recent developments. The company presented promising updates from its Phase 1b/2 MyPeak-1 study, particularly in Cohort 1, where patients showed significant improvements in symptoms, moving to an asymptomatic state. These encouraging signs of efficacy, although still requiring further clarity on specific protein levels, suggest potential for the TN-201 treatment.
Moreover, the expert opinion shared during a KOL dinner highlighted the excitement around MYBPC3 as a target in gene therapy, given its high prevalence and unmet medical needs. Despite some challenges in data continuity and variability among patients, the potential effectiveness of TN-201 in addressing these needs, combined with the strategic focus on ensuring evaluable data in future studies, supports the optimistic outlook for Tenaya Therapeutics.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNYA in relation to earlier this year.